Fut, nem toboroz2. fázis
The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia
A legfontosabb adatok
- Ki végzi
- Herlev Hospital
- Hol
- Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 15 fő, tervezett
- Kezdés
- 2026. jún. 30.
- Várható befejezés
- 2027. ápr. 15.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. október 14.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Signed informed consent by participant
- Signed informed consent by participant’s partner (must just be obtained before the participant starts treatment at Visit 1), if applicable, regarding blood samples, data col-lection about fertility treatment as well as pregnancy and pregnancy outcome
- 18-55 years
- Azoospermia verified by at least 2 semen samples, average semen volume >= 1,0 ml with no identifiable sign of obstruction (samples taken at Visit -1 and at Visit 0 prior to confirmation of eligibility and dosing)
- Serum AMH or Inhibin B level above the lower limit of quantification (LLOQ) at screening or within 6 months prior to screening
- Testosterone < 15 nmol/L at screening or within 6 months prior to screening
- Serum estradiol above the lower limit of normal range (48 pmol/L) at screening or within 6 months prior to screening
Ki nem vehet részt
- Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: o Herbal products and non-routine vitamins o Insulin o Medication such as systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics
- Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
- Hematocrit >50% at screening or within 6 months prior to screening
- Current abuse of steroids
- Prior thromboembolic event within the last 24 months
- Klinefelter or other major genetic conditions including large deletions on sex chromo-somes
- Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
- Severe chronic diseases requiring daily medication
- Serum prostate specific antigen (PSA) > 3 ng/mL at screening or within 6 months prior to screening
- Osteoporosis requiring medical treatment
- Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
- Average testis size > 20 mL unless obstruction has been excluded
- TESE procedure < ½ year ago
- LH concentration > 15 IU/L at screening
- BMI > 45 kg/m2
- Cardiovascular event within the last 6 months judged as significant by the investigator
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The aim of this intervention is to investigate whether the aromatase inhibitor, Leflutrozole, can improve semen quality in a subgroup of infertile men
Adatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- A regiszteradat frissítve
- 2026. október 14.